When testing for COVID-19, physicians and patients need to KNOW NOW
dianax is on a mission to create a step change in COVID-19 diagnostics by enabling clinical tests to happen ANYWHERE, ANYTIME and for ANYONE.
We have partnered with experts in rapid diagnostics – BioSpeedia (a spin-off of Institut Pasteur) – to bring to market a reliable test for rapid detection and differentiation of antibodies to novel coronavirus SARS-CoV-2. The COVID19SEROSpeed-IgM-IgG Rapid Test is now distributed by dianax in Italy, Belgium, Luxembourg, the Netherlands, Greece, Spain and Portugal.
Coming soon… the latest innovation in COVID-19 testing from dianax. Pan-European studies are underway to validate the dianax COVID KnowNow solution, combining the convenience of rapid, reliable antibody testing with the analytical power and connectivity of the dianax COVID-AI platform.*
By bringing laboratory-grade disease screening, diagnosis and monitoring to the patient, dianax is taking diagnostics straight to the POINT OF NEED. For the first time ever – patients and physicians will be able to KNOW NOW.
There is no time to wait:
the time is NOW
We are seeing a tectonic shift in healthcare infrastructure as we know it, powered by the smartphone revolution, and dianax is at the cutting-edge of mobile diagnostic transformation. Our device may be tiny but the implications are immense. While HbA1c-glycated hemoglobin blood testing for diabetes is our primary focus, the dianax lab-on-a-chip can test any protein extracted from bodily fluids (blood, urine, saliva), and so has the potential to transform diagnostic testing across a number of therapy areas.
We believe that rapid detection combined with informed decision-making will optimize treatment and improve patient outcomes. From expediting the screening, diagnosis and management of chronic diseases, such as diabetes or anemia, to detecting bacterial respiratory infections to prevent overuse or misuse of antibiotics, dianax will bring fast, reliable and affordable diagnostics to the POINT OF NEED – anytime, anywhere, for anyone.
We understand that when it comes to people’s health, to KNOW NOW really does matter.
Across the world …
1 in 2
people have iron deficiency anemia5
people are killed each year by antibiotic resistant infection6
We are indebted to those in the European Commission who recognized early on the extraordinary potential of our technology in changing the face of diagnostic testing and awarded a significant grant through their Horizon 2020 Program. This flagship initiative is designed to facilitate ‘breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market’, and we are committed to doing just that.
- Yole Développement. Point-of-Need Testing: Application of Microfluidic Technologies 2016 report. September 2016.
- Larsson A, et al. Ups J Med Sci. 2015;120(1):1–10 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389002/ [Accessed 10 Dec 2017]
- European Steering Group for Sustainable Healthcare
https://www.sustainable-healthcare.com/?gclid=EAIaIQobChMIx_DavY3_1wIVwbftCh3JtAIrEAAYASAAEgKq_vD_BwE [Accessed 10 Dec 2017]
- International Diabetes Federation (IDF) Diabetes Atlas – 8th Edition 2017 http://www.diabetesatlas.org [Accessed 25 January 2018]
- World Health Organization. Micronutrient deficiencies. http://www.who.int/nutrition/topics/ida/en/ [Accessed 25 January 2018]
- Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: Final Report and recommendations.
https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Accessed 25 January 2018]